Q1 Earnings Forecast for EBS Issued By HC Wainwright

Emergent BioSolutions Inc. (NYSE:EBS) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for Emergent BioSolutions in a research report issued on Friday, March 21st. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings of $0.87 per share for the quarter. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q2 2026 earnings at $1.04 EPS, Q3 2026 earnings at $1.11 EPS and Q4 2026 earnings at $0.81 EPS.

Emergent BioSolutions (NYSE:EBS) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40. The company had revenue of $194.70 million during the quarter, compared to the consensus estimate of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period in the previous year, the firm posted ($0.77) earnings per share.

Separately, StockNews.com downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Trading Down 0.6 %

NYSE EBS opened at $5.70 on Monday. The company has a market capitalization of $309.45 million, a PE ratio of -1.39 and a beta of 1.80. The company has a fifty day moving average of $8.48 and a 200 day moving average of $8.73. Emergent BioSolutions has a 1 year low of $1.82 and a 1 year high of $15.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EBS. American Century Companies Inc. raised its position in shares of Emergent BioSolutions by 23.4% during the 4th quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company’s stock worth $20,437,000 after purchasing an additional 404,667 shares during the last quarter. State Street Corp raised its position in shares of Emergent BioSolutions by 864.7% during the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after purchasing an additional 1,713,200 shares during the last quarter. Invesco Ltd. raised its position in shares of Emergent BioSolutions by 70.9% during the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after purchasing an additional 638,995 shares during the last quarter. Millennium Management LLC raised its position in shares of Emergent BioSolutions by 83.0% during the 4th quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock worth $14,167,000 after purchasing an additional 671,947 shares during the last quarter. Finally, Oak Hill Advisors LP acquired a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $9,296,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Insiders Place Their Bets

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the transaction, the director now owns 101,100 shares in the company, valued at approximately $589,413. This represents a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.